» Articles » PMID: 25126543

Ligation Strategies for Targeting Liposomal Nanocarriers

Overview
Journal Biomed Res Int
Publisher Wiley
Date 2014 Aug 16
PMID 25126543
Citations 50
Authors
Affiliations
Soon will be listed here.
Abstract

Liposomes have been exploited for pharmaceutical purposes, including diagnostic imaging and drug and gene delivery. The versatility of liposomes as drug carriers has been demonstrated by a variety of clinically approved formulations. Since liposomes were first reported, research of liposomal formulations has progressed to produce improved delivery systems. One example of this progress is stealth liposomes, so called because they are equipped with a PEGylated coating of the liposome bilayer, leading to prolonged blood circulation and improved biodistribution of the liposomal carrier. A growing research area focuses on the preparation of liposomes with the ability of targeting specific tissues. Several strategies to prepare liposomes with active targeting ligands have been developed over the last decades. Herein, several strategies for the functionalization of liposomes are concisely summarized, with emphasis on recently developed technologies for the covalent conjugation of targeting ligands to liposomes.

Citing Articles

Advancements in Liposomal Nanomedicines: Innovative Formulations, Therapeutic Applications, and Future Directions in Precision Medicine.

Izadiyan Z, Misran M, Kalantari K, Webster T, Kia P, Basrowi N Int J Nanomedicine. 2025; 20:1213-1262.

PMID: 39911259 PMC: 11794392. DOI: 10.2147/IJN.S488961.


Preclinical advance in nanoliposome-mediated photothermal therapy in liver cancer.

Tang L, Yang X, He L, Zhu C, Chen Q Lipids Health Dis. 2025; 24(1):31.

PMID: 39891269 PMC: 11783920. DOI: 10.1186/s12944-024-02429-x.


Brain-targeted drug delivery - nanovesicles directed to specific brain cells by brain-targeting ligands.

Moreira R, Nobrega C, de Almeida L, Mendonca L J Nanobiotechnology. 2024; 22(1):260.

PMID: 38760847 PMC: 11100082. DOI: 10.1186/s12951-024-02511-7.


Overcoming the Low-Stability Bottleneck in the Clinical Translation of Liposomal Pressurized Metered-Dose Inhalers: A Shell Stabilization Strategy Inspired by Biomineralization.

Huang Y, Chang Z, Gao Y, Ren C, Lin Y, Zhang X Int J Mol Sci. 2024; 25(6).

PMID: 38542235 PMC: 10970625. DOI: 10.3390/ijms25063261.


Liposomal Nano-Based Drug Delivery Systems for Breast Cancer Therapy: Recent Advances and Progresses.

Yazdan M, Naghib S, Mozafari M Anticancer Agents Med Chem. 2024; 24(12):896-915.

PMID: 38529608 DOI: 10.2174/0118715206293653240322041047.


References
1.
Chen R, Knutson J . Mechanism of fluorescence concentration quenching of carboxyfluorescein in liposomes: energy transfer to nonfluorescent dimers. Anal Biochem. 1988; 172(1):61-77. DOI: 10.1016/0003-2697(88)90412-5. View

2.
Jolck R, Feldborg L, Andersen S, Moghimi S, Andresen T . Engineering liposomes and nanoparticles for biological targeting. Adv Biochem Eng Biotechnol. 2010; 125:251-80. DOI: 10.1007/10_2010_92. View

3.
Chang H, Yeh M . Clinical development of liposome-based drugs: formulation, characterization, and therapeutic efficacy. Int J Nanomedicine. 2012; 7:49-60. PMC: 3260950. DOI: 10.2147/IJN.S26766. View

4.
Petersen A, Hansen A, Gabizon A, Andresen T . Liposome imaging agents in personalized medicine. Adv Drug Deliv Rev. 2012; 64(13):1417-35. DOI: 10.1016/j.addr.2012.09.003. View

5.
Haran G, Cohen R, Bar L, Barenholz Y . Transmembrane ammonium sulfate gradients in liposomes produce efficient and stable entrapment of amphipathic weak bases. Biochim Biophys Acta. 1993; 1151(2):201-15. DOI: 10.1016/0005-2736(93)90105-9. View